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Abstract          
         Modern science is currently working to characterize the beneficial compounds from 
mushrooms and their potential as pharmaceutical drugs. In this thesis, eight British Columbian wild 
mushroom collections (3 species), comprising Fomitopsis pinicola, Phaeolus schweinitzii and 
Phaeolus sp., were screened for growth-inhibitory potential. Out of 28 crude extracts, 15 exhibited 
strong growth-inhibitory activity. For the Phaeolus sp. collection, liquid-liquid extraction, size-
exclusion chromatography and high-performance liquid chromatograph-mass spectrometry (HPLC-
MS) were used to purify the growth-inhibitory compound of interest. NMR analyses confirmed its 
identity as hispidin, a known potent anti-cancer compound. Another compound with a mass to charge 
ratio of 283.2 in hexane extract of Phaeolus sp. was detected by HPLC-MS. This study provides the 
foundational work for further isolation of small molecule(s) from the three mushroom species and 
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Chapter 1 Introduction and literature review 
1.1 Cancer and its properties 
1.1.1 What is cancer 
     Cancer is a term used for specific diseases in which abnormal cells divide uncontrollably 
resulting in cell invasion and metastasis (Clark & Vignjevic, 2015). Cancer cells can spread to 
other parts of the body through the blood and lymphatic systems. The human body is made up 
of many different types of cells, such as skin, muscle, and blood cells. Many normal cells in 
our body are continually dividing to create new cells, and these healthy cells stop reproducing 
when enough cells are present (Mair, 2010). However, when an error occurs in the 
manufacturing of a new cell, that cell may become a cancer cell. In addition to an error in cell 
development, cancer cells do not have the internal system causing the cell to die after a certain 
time and this leads to the formation of abnormal cells. When this occurs, the cells can 
proliferate and build up a mass of tissue, called a tumor, or abnormal cells can crowd out the 
good, healthy cells, which occurs in leukemia or other cancers affecting the blood.  
       Cancer is a broad term that encompasses a complex group of more than 100 different types 
of cancerous diseases that can develop in the human body (Hanahan & Weinberg, 2000). Most 
of these can be considered as chronic diseases, representing one of the main health problems 
in the 21st century and the leading cause of death worldwide (Bray et al., 2018).  It is reported 
that cancer is the second most common cause of death among children between the ages of 5 
and 14 in the WHO European region (Kyu et al., 2016). As a chronic disease, cancer often 
leads to death or can have long-term devastating effects on an individual. Thus, finding 
effective cures and treatments for cancer is a major priority for the whole world in this century. 
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1.1.2 Conventional cancer treatment 
        Up to now, conventional cancer treatment mainly consists of surgery, chemotherapy and 
radiation therapy, depending on the type of cancer and the stage of tumor development inside 
the body (Gibbs, 2000).  Surgery is the most common form of cancer treatment and can be used 
by itself or in combination with other treatments (Arruebo et al., 2001). Common side effects 
from surgery are specific to the type of surgery done, which includes (but is not limited to) pain 
(often temporary), fatigue, risk of infection at the surgical site and organ dysfunction. 
Chemotherapy involves the use of drugs to destroy cancer cells; it is an effective and widely 
used treatment in most types of malignancies (Chabner & Roberts, 2005). The side effects of 
the chemotherapy will vary depending on the type of anti-cancer drug combination used, the 
dose of the anti-cancer drugs, and the frequency of treatments. Chemotherapy is a systemic 
treatment that results in the elimination of both healthy and cancerous cells (Aslam et al., 2014). 
Another treatment alternative is radiation therapy (or radiotherapy), which often uses X-rays 
to kill or damage cancer cells. Radiation is given before, during or after other treatments. The 
goal of radiation is to damage as many cancer cells as possible without harming healthy tissue 
(Baskar et al, 2014). 
         The major problem with these conventional therapies, especially radiotherapy and 
chemotherapy, is that they invariably result in damage or weakening of the patient’s natural 
immunological defenses, and cause a number of side effects, with serious damage and suffering 





1.1.3 Cancer in Canada 
         Almost half of Canadians will suffer from cancer in their lifetime, and about one-quarter 
of Canadians are expected to die from the disease (Statistics Canada, 2014). Cancer is the 
leading cause of death in Canada (Figure 1), and is responsible for 30% of all deaths, followed 
by cardiovascular diseases (heart and cerebrovascular diseases), accidents, and chronic lower 
respiratory diseases. In 2019, an estimated 82,100 Canadians were expected to die from cancer. 
Such a large number of cancer deaths has huge implications on the demand of health care and 
support services (Canadian Cancer Statistics). 
 
             
 
Figure 1 Proportion of deaths due to cancer and other causes in Canada, for 2016 
(Statistics Canada, 2016). 
         Cancer is also a major cause of premature mortality, according to the data measured by 
potential years of life lost (PYLL) (Canadian Vital Statistics Death database, Statistics Canada, 
2014-2016). PYLL is a summary measure of premature mortality that accounts for deaths 
5 
 
occurring at younger ages. As indicated, it tends to be more influenced by deaths from diseases 
and injuries affecting children and young adults, for whom the potential years of life are greater. 
During the period between 2014 and 2016, the PYLL for all cancers combined was almost 
1,411,100. This is more than any of the other leading causes of premature death in Canada 
(Figure 2). 
         
Figure 2 Selected causes of death and their associated potential years of life lost (PYLL), 
in Canada, for the period 2014–2016.  
1.2 Natural products as a source for drug discovery 
1.2.1 Natural products in history 
         Nature has been a source of medicinal agents for thousands of years. Plants, fungi and 
animals have been used as sources for the treatment of human diseases (Lahlou, 2007). The 
earliest records of natural products were written on clay tablets in cuneiform script, and are 
from Mesopotamia (2600 B.C.); they documented oils from Cupressus sempervirens (Cypress) 
and Commiphora species (myrrh), which are still in use today to treat coughs, colds and 
inflammation. The best known Egyptian pharmaceutical record is the Ebers Papyrus, dating 
6 
 
from 1500 B.C.; this documented some 700 drugs (mostly plants) including gargles, pills, 
infusions, and ointments (Cragg & Newman, 2005). The Chinese Materia Medica (1100 B.C.), 
Shennong Herbal (~100 B.C., 365 drugs) and the Tang Herbal (659 A.D., 850 drugs) also 
contain numerous records on the use of natural products (Cragg & Newman, 2005). 
      In the ancient western world, the Greeks contributed to the development of the use of herbal 
drugs. The natural scientist, Theophrastos (~300 B.C.) dealt with medicinal herbs, and the 
physician Dioscorides (100 A.D.), recorded the collection, storage and uses of medicinal herbs.  
During the Dark and Middle Ages (5th to 12th centuries), the monasteries in countries such as 
England, Ireland, France, and Germany preserved the remnants of this western knowledge. The 
Arabs were the first to establish privately owned drug stores in the eighth century, and the 
Persian pharmacist, physician and philosopher Avicenna, contributed much to the sciences of 
pharmacy and medicine through works such as Canon Medicinae (Cragg & Newman, 2005). 
1.2.2 Why are natural products useful for drug discovery 
       Worldwide, it is estimated that less than 10% of all natural products have been evaluated 
for biological activity; many more useful novel natural compounds still await discovery (Cragg 
& Newman, 2005). Natural products have evolved and adapted over millions of years through 
defense against bacteria, insects and fungi, or interference with competing organisms, to 
become unique, structurally diverse secondary metabolites. Whatever their precise role, many 
natural products can reach human receptor sites on or within cells, just as a drug must do. The 
large number of pure natural products which have been found to interact with specific 
mammalian receptors testifies to the inherent bioactivity in natural products (Beutler, 2009).  
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        The value of natural product chemistry is in providing novel molecular skeletons and 
functionalities, which may be used as templates for the development of new drugs. Recently, 
pharmaceutical scientists have experienced difficulty in identifying new lead structures, 
templates and scaffolds in the finite world of chemical diversity (Patwardhan et al., 2004). A 
number of synthetic drugs have adverse and unacceptable side effects (Karimi et al., 2015). 
There have been impressive successes with botanical medicines, most notably quinghaosu, 
artemisinin from Chinese medicine (Tu, 2011), its derivative was found to treat human cervical 
cancer in clinical trial (Jansen et al., 2011). 
1.2.2.1 Natural products from plants 
       Plants have been known for their medicinal uses for thousands of years. About 80% of 
people in developing countries of the world still rely on plant-based medicines for primary 
health care (Farnsworth et al., 1985). Plant medicines have a long history of use for the 
treatment of cancer (Hartwell, 1982). The most widely used breast cancer drug is paclitaxel, 
which was originally isolated from the bark of T. brevifolia in 1962 by the United States 
Department of Agriculture (Cragg, 1998). Another example is tubocaurarine, originally 
isolated from the climbing plant, Chondrodendron tomentosum, and is one of the active 
constituents in a muscle relaxant used in surgical operations (Dewick, 2002). 
1.2.2.2 Natural products from fungi 
       Like plants, fungi have been a part of human life for thousands of years. Fungi have been 
utilized in various aspects from food (mushrooms), alcoholic beverages (yeasts), traditional 
medicine (Hays & Watson, 2019), and to human rituals (Samorini, 1992). 
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      Fungi have been used as medicine since the Neolithic and Paleolithic eras (Samorini, 2001). 
Mushrooms have been used in health care for treating simple and age-old common diseases 
like skin diseases, as well as present day health challenges including pandemic diseases like 
AIDS (Chang, 2006). They possess many biological activities including anti-bacterial, anti-
inflammatory, anti-oxidant and anti-cancer properties. Compounds isolated from mushrooms 
such as Ganoderma pfeifferi Bres., Lentinus edodes (now Lentinula edodes (Berk.) Pegler)  
and Cortinarius basirubescens J.B. Cleland & J.R. Harris showed antimicrobial activity against 
pathogenic microorganisms like bacteria associated with nosocomial infections. (Alves et al., 
2012). Fractions from the mushroom Inonotus obliquus (Ach. ex Pers.) Pilát were found to 
have anti-inflammatory effects on NO production and NF-κB luciferase activity in macrophage 
RAW 264.7 cells (Ma et al., 2013). A water extract from L. edodes showed potent anti-oxidant 
activity in three different assays (Cheung et al., 2003). Mushrooms are also one of the main 
sources for anticancer drug discovery (Newman & Cragg, 2012). 
1.3 Mushrooms as a source of cancer treatment or prevention 
1.3.1 Medicinal mushrooms and their anti-tumor activities 
         Conventional cancer therapies have side effects, as mentioned above; recently, some 
researchers have focused on treating cancers and improving the patient’s quality of life by 
modifying the host’s biological response against the malignant invasion. Immunotherapy is 
now gaining more attention, since it causes considerably fewer side effects and helps to 
overcome cancer growth (Farkona et al., 2016). Immunotherapy uses the body’s immune 
system, either directly or indirectly, to fight cancer or to reduce the side effects that may be 
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caused by some severe cancer treatments (Kakimi et al., 2009). Figure 3 illustrates some 
medicinal mushrooms with anti-cancer potential properties. 
                
Figure 3 Some medicinal mushrooms with anti-cancer potential (Modified from Patel, S., & 
Goyal, A., 2012) 
        There are many forms of biological immunotherapeutic agents, such as monoclonal 
antibodies, interferons, cancer vaccines and nonspecific immuno-modulating agents. Many 
mushroom-derived extracts are recognized as immuno-modulators or biological response 
modifiers (Lull et al., 2005, Novak & Vetvicka, 2009).  Medicinal mushrooms, in particular, 
are not only hubs for a myriad of immuno-modulators, but also a source of anti-cancer agents, 
which could interfere with specific cellular signal transduction pathways linked to cancer 
development and progression (Kudugunti et al., 2010). Recently, more than 30 species of 
identified medicinal mushrooms (e.g, Phellinus linteus (Berk. & M.A. Curtis) Teng, Grifola 
frondosa (Dicks.) Gray, Hypsizygus marmoreus (Peck) H.E. Bigelow and Flammulina 
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velutipes (Curtis) Singer have showed antitumor activity in experimental studies (Wasser, 
2011). Medicinal mushrooms show therapeutic action against the development of cancer cells, 
primarily because they contain a number of biologically active high and low molecular weight 
compounds (Lee & Hong, 2011, Li et al., 2015). 
1.3.1.1 High molecular weight compounds   
       The high molecular weight compounds which have been found in medicinal mushrooms 
are mainly polysaccharides, proteins, and polysaccharide-protein complexes (Wasser, 2003). 
For example, lentinan, an anti-tumor polysaccharide produced by L. edodes, this mushroom is 
widely consumed as a nutritional health food throughout the world, especially in Asia, and is 
known to possess strong host-mediated anti-cancer activity by activating the immune system 
(Cheung, 2008). Mushrooms can also produce a large number of proteins with significant 
biological activities (Wong et al., 2010). Lectins, which are proteins that bind to cell surface 
carbohydrates, have the ability to produce cell agglutination and show several anti-proliferative 
and anti-tumor activities against cancer cell lines (Zhang et al., 2009). Lectins are abundant in 
many species of mushroom, including Agaricus bisporus (J.E. Lange) Imbach and Pleurotus 
ostreatus (Jacq.) P. Kumm. (Hassan et al., 2015). Medicinal mushrooms have immuno-
stimulatory activity not only because of their bioactive polysaccharides, but also by having 
varying combinations of polysaccharide-protein complexes (Moradali et al., 2007). For 
instance, Agaricus subrufescens Peck is a well-known mushroom having several biologically 
active metabolites, including polysaccharides and glycoproteins that are thought to be 
responsible for its immuno-stimulant and anti-tumor properties (Wisitrassameewong et al., 
2012).  Table 1 shows a list of some biologically active large molecules from mushrooms.  
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Table 1 Large compounds from mushroom and their biological properties 








(Barad et al., 
2018) 
L. edodes D-glucopyranose Immunomodulatory 


























Russula delica Fr. Lectin Anti-proliferative 
(Zhao et al., 
2010) 









(Chen et al., 
2009) 
Ganoderma lucidum 
(Curtis) P. Karst. 
Glycoprotein Antioxidant activity 













1.3.1.2 Low molecular weight compounds 
         Mushrooms produce a variety of complex low molecular weight compounds with diverse 
chemical compositions, such as phenolic compounds, polyketides and triterpenoids 
(Elisashvili, 2012). Ergosterol is a provitamin form of vitamin D2 in human nutrition, it 
abundant in mushrooms such as A. subrufescens and Lentinula edodes (Wisitrassameewong et 
al, 2012, Jasinghe & Perera, 2005). Grifolin is a natural biologically active metabolite that was 
isolated from the mushroom Albatrellus confluens (Alb. & Schwein.) Kotl. & Pouzar; it was 
identified as a potential antitumor agent that can inhibit cancer cell growth by inducing 
apoptosis in vitro (Ye et al., 2005). Grifolin could also exert anti-oxidative activity and 
antimicrobial activity (Quang et al., 2006). Medicinal mushrooms have been reported to 
produce various polyphenolic pigments, known as the styrylpyrone class of phenols derived 
from polyketide pathways, which show significant biological effects including anti-cancer 
properties (Lee & Yun, 2011). For example, some early studies have shown that hispidin, is 
more cytotoxic toward cancerous cells (pancreatic duct and keratinocyte) than normal cells 
(Gonindard et al., 1997).  Some potent biological small molecules purified from the fruiting 
bodies of mushrooms are shown in Table 2. 
Table 2 Small compounds from mushrooms and their biological properties 
Mushroom Compounds Biological activity Reference 
Agaricus blazei 
Murill 
Ergosterol Growth-inhibitory activities 
(Takaku et al., 
2001) 
A. confluens Grifolin Growth-inhibitory activities 






Irofulven Immuno enhancing 
(Fung & Tan, 
2015) 














O.K. Mill. & Nishij. 
Hericerin Induction of apoptosis 
(Li et al., 
2015) 






Hispidin Antioxidant activity 




Chang & W.N. 
Chou 










(Zhang et al., 
2018) 
 
1.3.2 Experimental studies with mushrooms 
       The mushroom Agaricus blazei is used as food, as natural remedy for cancer prevention, 
and as adjuvant in cancer treatment (Firenzuoli et al., 2008). There is also a similar study about 
adjuvant properties that investigated the combination of A. blazei extract with marine 
phospholipids on myeloma sp2 tumor suppression when administrated orally. Results of this 
in vivo study indicated that oral administration of A. blazei extract, with or without 
encapsulated liposomal form, suppressed myeloma in mice. Additionally, the study suggested 
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that the anti-tumor effect of marine phospholipid occurred without weight loss, which might 
indirectly affect the treatment of the disease (Murakawa et al., 2007).  
       The components of the fungus Polyozellus multiplex (Underw.) Murrill were tested in vitro 
against human gastric cancer cells as well as other cancer cells. The water fraction of P. 
multiplex dramatically increased glutathione S-transferase (GST) and superoxide dismutase 
activities, showing a tendency of increasing glutathione (GSH) levels, as compared to the N-
methyl-N-nitro-N-nitrosoguanidine (MNNG) group alone (Lee & Nishikawa, 2003). The 
results demonstrated that proliferation of distinct types of cancer cells could be significantly 
inhibited by the P. multiplex water fraction, suggesting its possible use as a chemo-prevention 
agent in stomach cancer (Lee & Nishikawa, 2003). 
1.3.3 Clinical studies with mushrooms 
       Some medicinal mushrooms with anti-cancer effects, subjected to human clinical trials, 
are indicated in Table 3. 
Table 3 Summary of human clinical studies in anticancer effects of medicinal mushrooms 
Mushroom 
Type of study 















habitual mushroom intake 
and epithelial ovarian 
cancer 
 













Improve tumor response 
















Combine treatment of 





        The first observational report associating mushrooms (A. bisporus and shiitake) intake and 
ovarian cancer was conducted in China; the participants were 500 patients diagnosed with 
ovarian cancer, along with a control group of 500 healthy participants. The patients with 
ovarian cancer consumed less mushrooms than the controls, and results showed that mushroom 
intake at increasing levels is associated with a decreasing risk of ovarian cancer (Lee et al., 
2013). In another clinical trial, the effectiveness of the mushroom Pleurotus cornucopiae 
(Paulet) Rolland was evaluated and the mushroom extract was shown to exert immuno-
potentiation for several diseases including cancer (Tanaka et al., 2016). P. cornucopiae has also 
been traditionally consumed by Japanese people due to its cancer preventative properties 
(Tanaka et al., 2016). 
        Ganoderma lucidum, also known as Reishi mushroom, is widely believed to be 
responsible for longevity and general well-being; recently, it has also been used as an 
alternative medicine in cancer treatment. A review has evaluated the clinical activities of G. 
lucidum to prolong survival time, tumor response, and the quality of life in cancer patients (Jin 
et al., 2016). This study demonstrated that the incorporation of G. lucidum extract treatment 
can enhance tumor response of lung cancer in conventional therapy, and is believed to improve 
immunity by stimulating T-lymphocyte proliferation, suggesting that it is a promising adjuvant 
to restrain the undesired immunosuppressive effect of many chemotherapeutic drugs. 
Furthermore, this study reported an improvement in the quality of life of cancer patients who 
were treated with G. lucidum, and concluded the absence of serious toxicity through the clinical 




1.4 Mushrooms in British Columbia  
        There is general acceptance among mycologists that the number of global fungal species 
is between 1 to 5 million (Blackwell, 2010). It is believed that there are about 150,000-160,000 
species of mushrooms in the world, and approximately 10% have been explored (Wasser, 
2014). This large diversity provides a huge sample source from which new anti-cancer 
compounds can potentially be discovered, purified, identified, and further studied for 
pharmaceutical use. Besides the work from Dr. Lee’s lab at UNBC, only two other studies have 
been conducted on the bioactivity of mushrooms in Canada. The first one was the discovery of 
a novel compound, ganoderma aldehyde, derived from the mushroom Ganoderma applanatum 
(Pers.) Pat. which was collected in the forest of British Columbia (BC). However, the 
bioactivity of the compound isolated was not described in detail (Ming et al., 2002). Another 
study involved the mushroom I. obliquus, collected from Manitoba and was shown to exert 
anti-inflammatory activity on Raw 264.7 macrophage cells. However, no further studies were 
done to identify and purify the active compound (Van et al., 2009).  
        Currently, there are several ongoing research projects being carried out in Dr. Lee’s lab, 
focusing on screening a variety of mushrooms collected from British Columbia for their anti-
cancer properties (anti-proliferative, immuno-stimulatory and anti-inflammatory) (Smith et al., 
2017; Deo et al., 2019). In one study, 17 different fungal species were collected from multiple 
locations in Haida Gwaii and were screened for anti-cancer properties (Deo et al., 2019); 
among these mushrooms, Amanita augusta Bojantchev & R.M. Davis, Phellodon atratus K.A. 
Harrison, Guepinia helvelloides (DC.) Fr., Chroogomphus tomentosus (Murrill) O.K. Mill., 
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Laetiporus conifericola Burds. & Banik, and Inocybe sp. were shown to have strong anti-
proliferative and anti-inflammatory activities. In another study, a polysaccharide extracted 
from the fungus P. involutus, collected from Prince George, BC, was shown to possess growth-
inhibitory activity against several cancer cell lines and could also trigger apoptosis of cancer 
cells (Barad et al., 2018). Yet another study also revealed that an anti-inflammatory 
polysaccharide, successfully isolated from Echinodontium tinctorium (Ellis & Everh) Ellis & 
Everh. exhibited activity both in vitro and in vivo (Javed et al., 2019a). A companion study, 
testing the methanol extract from I. obliquus, showed similar anti-inflammatory activities 
(Javed et al., 2019b). A recent study, characterizing 3 compounds from the terricolous polypore 
Albatrellus flettii Morse ex Pouzar, documented the suppression of KRAS expression in human 
colon cancer cells (Yaqoob et al., 2020). Many other studies are ongoing in the lab, including 
my project. Therefore, taking into account the limited research conducted on the bioactivity of 
BC wild mushrooms, it seemed logical to further study the potential therapeutics of Canadian 
mushrooms in the field of cancer.            
1.5 Future prospects of drug discovery from mushrooms 
        Today, some medicinal mushrooms are identified as sources for biologically active 
metabolites with potential anti-cancer properties. The bioactive metabolites from medicinal 
mushrooms could offer beneficial effects, not only as pharmaceutical drugs but also as a novel 
class of supportive products (Jiang & Silva, 2010). Examples of the available drug products 
and supplementary foods developed from medicinal mushrooms claiming to provide beneficial 




Figure 4 Examples of products marketed with claimed immune stimulatory and anti-
cancer properties containing mushrooms or their extracts 1. Dr Myko San—Health from 
Mushrooms 2. Ganoderma lucidum Spore 3. Grifron Maitake Mushrooms 4. I’m-Yunity® 5. MC-S (Metabolic 
Cell Support) 6. MycoPhyto® Complex 7. Red Reishi 8. Super Royal Agaricus Mushroom. Figure modified from 
De Silva et al. (2012) 
         Medicinal mushrooms contain many active metabolites that can be used as support 
remedies for cancer treatments (Evidente et al., 2014). The above examples just describe a few 
studies about anti-cancer properties of mushrooms, and the numbers will keep increasing as 
more mushrooms are tested. With articles citing their medicinal potential, it is clear that 
medicinal mushrooms would serve as ideal candidates for the further discovery of a potential 
anti-cancer drug. 
1.6 Research goals 
      Based on the fact that relatively limited studies have been done on bioprospecting wild 
mushrooms native to Canada, I set out to explore several wild mushrooms found in BC. The 
specific research objectives of my MSc. thesis are: 
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(i) To chemically extract and biologically assess eight Canadian mushroom 
collections (comprising 3 species in two genera, Fomitopsis and Phaeolus) for 
anti-cell viability activity. 
(ii) To purify and characterize the small molecule growth-inhibitors from the unique 
























Chapter 2 Evaluation of wild mushrooms collected in British Columbia for anti-cell 
viability activity 
     This chapter describes studies investigating eight mushroom collections from BC (including 
the 2 genera Fomitopsis and Phaeolus). Each sample was identified by morphological 
characteristics and DNA analysis. Samples were pulverized and two extraction techniques were 
employed using various parameters such as solvents, temperatures and time. Finally, extracts 
from each sample were screened for anti-cell viability activity against HeLa human cervical 
cancer cells. 
     About 40 species have been recorded in Fomitopsis genus worldwide (Li et al., 2013). Most 
species are parasitic on woody plants, and tend to cause brown rots (Cannon & Kirk, 2007). 
Fomitopsis pinicola (Sw.) P. Karst. is a brown-rot fungus, which grows on coniferous and 
broad-leaved trees and is widespread in north America, in addition to Asia and Europe 
(Rösecke et al., 2000). This mushroom belongs to the family Polyporaceae, the dried fruiting 
bodies of different Fomitopsis species have been used in folk medicine as haemostatics and 
anti-inflammation agents (Keller et al., 1996). Japanese people have widely cultivated this 
mushroom to be used as a health food source for growth regulation and diabetes (Högberg et 
al., 1999). In addition, F. pinicola has also been used as an anti-diabetic material in Korea as a 
traditional folk medicine (Lee et al., 2008). In Europe, F. pinicola is considered to be a nontoxic 
mushroom (Keller et al., 1996).  
     The genus Phaeolus is distributed in the northern hemisphere and Australia (Sinclair & 
Lyon, 1987 & Simpson & May, 2002), and the name is derived from the Ancient Greek word, 
meaning "dark" or "obscure" (Donk, 1960). The genus Phaeolus comprises 27 species 
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(Patouillard, 1900) and the most important one, from a forestry standpoint, is schweitnitzii. P. 
schweinitzii is a common root and butt pathogen of conifers in North America and Eurasia 
(Sinclair & Lyon, 1987). Schweinitzii root and butt rot is a major disease of older trees; it causes 
decay of the roots and lower stem and the resulting strength loss predisposes trees to windthrow 
and breakage (Fairweather, 2006). 
2.1 Materials and methods  
2.1.1 Collection and identification of wild mushrooms 
     All wild mushrooms were collected from Haida Gwaii, British Columbia in August 2015. A 
pocketknife or a hatchet was used to separate the mushroom from the tree substrate to which it 
was attached. The morphological descriptions such as shape, size and color were recorded, as 
well as location, habitat and surrounding vegetation to be used in mushroom identification. 
Paper bags were used for temporary storage of samples. After that, mushrooms were dried for 
further analysis. Two different methods were used to identify the mushrooms: macro-
morphological analysis and DNA analysis. 
2.1.1.1 Macro-morphological identification 
      This type of identification is based on morphological details and characteristics of the 
mushrooms, as different mushrooms will exhibit different morphological appearances such as 
cap, spore-bearing surface, stipe, veils and odor, which could help identify the samples 
preliminarily. I used the reference Mushrooms Demystified by David Aurora (1986) as an 
identification guide, as it is effective to determine the mushroom or narrow down the identity 
of the mushroom samples to family, genus and often species level. In addition, Matchmaker 
Mushroom ID Software (Gibson et al., 2010) was used for further identification of mushroom 
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samples. This software describes the details of over 4000 gilled and non-gilled mushroom 
species from the Pacific Northwest, and can help to identify the mushroom species with more 
detailed information. 
2.1.1.2 Identification of mushrooms using DNA analysis 
      Identification of mushroom based on morphology is simple and efficient, but it can be 
misleading due to several factors, like hybridization (Olson & Stenlid, 2002) and convergent 
evolution (Brun & Silar, 2010). DNA-based identification methods have emerged as an 
efficient way to distinguish species among diverse fungi (Raja et al., 2017). 
       Genomic DNA was extracted from collected mushrooms using a MoBio DNA PowerSoil 
Kit. After successful DNA extraction, ITS3 and NLB4 primers were used to amplify the 
sequences of the samples (Smith et al., 2017). The genomic DNA (gDNA) of mushroom 
samples were subjected to PCR using the conditions indicated in Tables 4 and 5. 
Table 4 PCR reaction protocols required to amplify the extracted DNA from the 
mushroom species. 
Component Volume used (μL) 
H2O 16 
10x Thermo Pol 
Buffer 
2.5 
dNTPs (2.5 mM) 2.5 
ITS3 (10 μM) 1 
NLB4 (10 μM) 1 
DNA template 1.5 







Table 5 PCR conditions for DNA amplification. 
Step Temp Time 
1 95 °C 5min 
2 95 °C 30sec 
3 52 °C 30sec 
4 72 °C 30sec 
5 72 °C 10min 
6 4 °C 10min 
       The exponentially amplified DNA samples were further subjected to gel electrophoresis 
to confirm the success of DNA amplification and ensure sufficient quantity for DNA 
sequencing. The post-PCR amplified DNA products needed to be cleaned using the QIAquick 
PCR kit. 
      The sequences obtained from Macrogen Corporation were compared with sequences 
available in the National Center for Biotechnology Information (NCBI) internet database, 
GenBank, using the Basic Local Alignment Search Tool (BLAST) program. The best Genbank 
match of mushroom species is shown in Table 6. The photographs and data on the mushrooms 
are shown in Table 7. 
Table 6 Identification of mushroom species using BLAST searches, along with the percent 
of matching bases between the unknown sample and the closest match. 
Identity Collected By 
Best GenBank Match 
(% similarity/ % coverage) 
Fomitopsis pinicola (50) 
Drs. Chow Lee, Wai Ming Li, 
Hugues Massicotte, Keith Egger, 
and Ms. Linda Tackaberry 
KC595922.1 
(98% / 100%) 
Fomitopsis pinicola (53) 
EF530947.1 
(100% / 100%) 
Fomitopsis pinicola (65) 
KC595922.1 
(98% / 100%) 
Fomitopsis pinicola (77) 
EF530947.1 
(100% / 100%) 
Phaeolus schweinitzii (58) 
KC581334.1 
(99% / 100%) 
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Phaeolus schweinitzii (60) 
KC581354.1 
(99% / 100%) 
Phaeolus sp. (71) 
MH277962.1 
(100% / 71%) 
Table 7 Collection location and photographs of the mushrooms collected from different           
locations in British Columbia. 
Collection 
Number 





Cape Fife Trail, Naikoon 
Park, Haida Gwaii, BC 





Cape Fife Trail, Naikoon 
Park, Haida Gwaii, BC 





Pesuta Shipwreck Trail, 
Naikoon Park, Haida 
Gwaii, BC 





Copper Rd-Sandspit area 
(towards Gray Bay, Haida 
Gwaii), BC 








Tlell, Crow's Nest Cafe, 
Haida Gwaii, BC 





Anvil Interpretive Trail, 
Tlell, Haida Gwaii, BC 





Anvil Interpretive Trail, 
Tlell, Haida Gwaii, BC 






Pesuta Shipwreck Trail, 
Naikoon Park, Haida 
Gwaii, BC 
August 25, 2015 
 
2.1.2 Chemical extraction of mushrooms 
     After collection, the mushroom specimens were dried at low heat (50 °C) and then 
powdered (Figure 5) using either a regular household blender or a hammer mill. 
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Figure 5 An example of a dried and powdered mushroom sample 
        The chemical extraction protocol has been established in Dr. Chow Lee’s lab: dried 
samples were extracted with four different solvents, firstly with 80% ethanol and 50% 
methanol, which were expected to obtain low molecular weight compounds. After this, the 
remaining mushroom powder was extracted using water, and then 5% sodium hydroxide. The 
water and 5% NaOH extract were expected to contain water-soluble polysaccharides. The first 
three solvent extractions were performed using the Dionex Accelerated Solvent Extractor 
(ASE) 350 Speed Extractor (Thermo Fisher) at 65°C and at a pressure of 1500 psi. The Dionex 
ASE 350 is an automated, easy and effective tool for sequential extraction (Richter et al., 1996). 
The 5% NaOH extract was done manually at 65°C as it will corrode the walls of the machine. 
The outline of the extraction process using the Speed Extractor is shown in Table 8: 
Table 8 Outline of the extraction process 
Dionex ASE 350 Extraction Process Duration 
Static extraction with rinse (80% ethanol) 4 cycles, 15 minutes per cycle 
Static extraction with rinse (80% ethanol) 4 cycles, 15 minutes per cycle 
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Static extraction with rinse (80% ethanol) 4 cycles, 15 minutes per cycle 
Static extraction with rinse (80% ethanol) 4 cycles, 15 minutes per cycle 
Manual Extraction Duration 
5% sodium hydroxide extraction 6 hours with constant stirring 
      The obtained mushroom extracts were labeled as E1, E2, E3 and E4 for 80% ethanol, 50% 
methanol, water, and 5% NaOH extracts respectively. 
2.1.3 Rotary evaporation, pH neutralization, dialysis, and lyophilization of the extracts 
     All extracts were further concentrated by eliminating the redundant solvent volume. This 
process was achieved by using a rotary evaporator. Once the volume of the extractions was 
reduced to a required amount, the extracts were subjected to pH neutralization. The pH range 
used as reference to neutralize the mushroom extracts was 6.90 to 7.10. For pH neutralization, 
either 2 M of NaOH or 2 M of HCl was added. After this, the extracts were dialyzed using 
Thermo Scientific SnakeSkin Dialysis Tubing (3.5K MWCO) for 24 hours in order to remove 
salts. Finally, extracts were lyophilized to become dried: the extracts were firstly frozen in -80 
ºC freezer and then lyophilized by using Labconco Freeze dryer (0.008 bar vacuum pressure 
and -80 ºC). Freeze-dried samples were stored at 4°C for subsequent experiments. For long-
term storage, dried samples were kept at -80°C.  
2.1.4 Preparation of stock solution and filter sterilization 
    To prepare stock solution, the solubility needs to be taken into account when making 
concentrated extracts. The extracts were analyzed first for their maximum solubility in an 
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appropriate solvent. After obtaining the stock solution of the extracts, the solutions were filter 
sterilized with 0.2 μm filters (Sarstedt, Nümbrecht, Germany). Finally, the filtered solutions 
were assessed for anti-cell viability activity. 
     Figure 6 outlines the chemical extraction and the downstream steps taken. 
 
Figure 6 Sequential chemical extraction 
2.1.5 Assessment for anti-cell viability activity  
2.1.5.1 MTT assay 
      MTT [3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide] is a water-soluble 
yellow dye and can be reduced to water-insoluble purple formazan crystals by the 
dehydrogenase system of active cells (Carmichael et al., 1987). The MTT tetrazolium assay is 
a popular tool in assessing cytotoxicity and cell viability (Van Meerloo et al., 2011). The test 
is based on enzymatic reduction of the lightly colored tetrazolium salt to its formazan of intense 
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purple-blue color; the concentration of the purple formazan makes it possible to estimate the 
number of viable cells, which can be quantified spectrophotometrically.  
   
Figure 7 (A) Chemical structure of MTT and its reduced formazan product; (B) 
absorption spectra of MTT 
      Dimethyl sulfoxide (DMSO) was used to dissolve formazan crystals. The absorbance at 
570 nm was measured on a spectrophotometer Synergy 2 multi-plate reader (BioTek®, USA) 
as formazan has the highest optical density at 570 nm (refer to Figure 7 B).  
2.1.5.2 Dose-dependent MTT assay to determine anti-cell viability activity  
      Dried mushroom extracts in powder were reconstituted in their respective suitable solvents, 
shown in Table 11. For extracts which were dissolved in water, the stock concentration was 
prepared at 20 mg/mL. As for methanol soluble extracts, the stock concentration was prepared 
at 40 mg/mL. The stock solutions were then filter sterilized using 0.2 μm filter (Sarstedt, 
Nümbrecht, Germany). 
     For the dose-dependent MTT assay, the stock solution was further diluted by adding EMEM 
(Eagle’s minimum essential media) supplemented with 10% fetal bovine serum (FBS) to make 
different doses of extracts. HeLa cells (ATCC®, Maryland US) cells were first subjected to 
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treatment with different concentrations (from 0.1 to 1 mg/mL) of the extracts for 48 hours and 
the MTT assay was performed.    
     The dose-dependent MTT assay was used to investigate the percent viability of HeLa cells 
after treating with different concentrations of mushroom extracts. HeLa cells were maintained 
in a T-25 flask with around 10 mL of Lonza Eagle’s Minimum Essential Medium (EMEM by 
VWR, ON, CA) supplemented with 10% v/v FBS. When reaching 80% of confluency, the 
growth media (EMEM+ 10% FBS) was removed from the flask and cells were washed with 4 
mL of Dulbecco’s Phosphate Buffer Saline (DPBS) (Lonza, Maryland), followed by 1 mL of 
Trypsin EDTA to remove cells which adhere to the bottom of T-25 flask surface. 
      Cells were plated into a 96-well plate. The plated cells at (1500 cells/100 μL/well) were 
incubated for 24 hours at 37°C in 5% CO2. After incubating for 24 hours, different 
concentrations of mushroom extracts were prepared with EMEM (containing10% FBS and the 
respective solvents) as shown in Table 9. 
Table 9 Representation of the different doses of mushroom extracts used for MTT assay. 


























1 2 0 50 50 0 300 300 
0.75 1.5 12.5 37.5 50 75 225 300 
0.5 1 25 25 50 150 150 300 
0.375 0.75 31.2 18.75 50 187.5 112.5 300 
0.25 0.5 37.5 12.5 50 225 75 300 
0.1 0.2 45 5 50 270 30 300 
0 0 50 0 50 300 0 300 
 Total Volume of 100 μL Total Volume of 600 μL 
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       Finally, the different doses of 100 μL mushroom extracts as well as the negative control 
(water or methanol) were added to the cells. Five replicates of each sample and control (same 
solvent in which the fractions were reconstituted) were included. The plate pattern is shown in 
Table 10. 
Table 10 Plate pattern (96-well) followed to screen different doses of extracts from 
selected mushroom samples, for their potential to exhibit anti-proliferative activity based 
on the MTT assay. 
 1 2 3 4 5 6 7 8 9 







































































G water water water water water water water water water 
      On day four, 50 μL of MTT diluted with EMEM solution (1 mg/mL) was added to the cells. 
The cells were incubated for three hours allowing the live cells to react with the MTT dye, and 
converting it to formazan crystals by mitochondrial reductase. Finally, the supernatant was 
removed and 150 μL of DMSO was added to each well to dissolve the formazan crystals. The 
absorbance at 570 nm was read using Synergy 2 multi-plate reader. The activity of various 
fractions was measured in percent cell viability compared to that of the control. Standard 
deviation was the measure of error for the MTT bioassay. Kaleidagraph© version 4.03 
(Synergy Software) was used to generate the graph for the acquired data. The workflow is 




Figure 8 Schematic representation of dose-dependent MTT assay protocol using HeLa 
Cells. 
2.2 Results and discussion 
2.2.1 Chemical extraction of mushrooms 
     The Dionex ASE 350 speed extractor was used to obtain E1, E2 and E3 crude extracts 
while the E4 5% sodium hydroxide extract was done manually using a hotplate. The summary 
of extraction results is shown in Table 11. 



















Fomitopsis pinicola (#50) 
 
5.403 
E1 80% Ethanol 0.174 3.22 Coarse powder Methanol 
E2 50% Methanol 0.093 1.72 Coarse powder Methanol 








Fomitopsis pinicola (#53) 
 
4.831 
E1 80% Ethanol 0.469 9.71 Coarse powder Methanol 
E2 50% Methanol 0.186 3.85 Coarse powder Methanol 
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Fomitopsis pinicola (#65) 
 
5.057 
E1 80% Ethanol 0.054 1.06 Coarse powder Methanol 
E2 50% Methanol 0.078 1.54 Coarse powder Methanol 








Fomitopsis pinicola (#77) 
 
4.987 
E1 80% Ethanol 0.322 6.46 Coarse powder Methanol 
E2 50% Methanol 0.113 2.27 Coarse powder Methanol 








Phaeolus schweinitzii (#57) 
 
5.316 
E1 80% Ethanol 0.406 7.68 Coarse powder Methanol 
E2 50% Methanol 0.415 7.81 Coarse powder Methanol 








Phaeolus schweinitzii (#58) 
 
5.325 
E1 80% Ethanol 0.210 3.94 Coarse powder Methanol 
E2 50% Methanol 0.216 4.06 Coarse powder Water 








Phaeolus schweinitzii (#60) 
 
5.345 
E1 80% Ethanol 0.189 3.53 Coarse powder Methanol 
E2 50% Methanol 0.292 5.46 Coarse powder Water 








      Generally, the extract E4 has the highest yield amongst all extracts except for mushroom 
sample #53 and #77. The lowest yields were obtained mostly for E3 water extracts. The highest 
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yield (16.39%) amongst all extracts was exhibited by E4 of P. schweinitzii (#58), while the 
lowest yield (0.85%) was exhibited by E3 of F. pinicola (#50). The physical appearance of 
these powder extracts were quite distinct. All E1 and E2 extracts were coarse powder. E3 and 
E4 extracts were generally fluffy in nature. All E1 and E2 extracts were dissolved in methanol 
except for E2 of P. schweinitzii #58 and #60 which was reconstituted in water. All E3 and E4 
extracts were soluble in water. 
2.2.2 Dose-dependent cell viability assessment of mushroom extracts using HeLa cells 
2.2.2.1 Fomitopsis pinicola (#50) 
      Results of the dose-dependent MTT assay of extracts 1-4 from Fomitopsis pinicola (#50) 
are shown in Figure 9. Extracts 1 and 2 significantly reduced cell viability to 40% at the lowest 
concentration of 0.1 mg/mL. Extract 3 also reduced the cell viability to around 20% at the doses 
of 0.75 and 1 mg/mL. In contrast, extract 4 did not appear to have any significant effect on cell 

































Figure 9 Dose-dependent assessment of cell viability by extracts from F. pinicola (#50) 
Different concentrations of crude extracts E1 (80% ethanol), E2 (50% methanol), E3 (water) 
and E4 (5% NaOH) were added to HeLa for 48 hours followed by assessment of cell viability 
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using MTT assay. The graph shows results from one biological replicate (n=1). Error bars are 
standard deviation. 
2.2.2.2 Fomitopsis pinicola (#53) 
      Results in Figure 10 show that extract 3 from Fomitopsis pinicola (#53) reduced the cell 
viability to around 20% at the doses of 0.75 and 1 mg/mL. Extracts 1 and 2 inhibited the cell 
viability to around 40% at the lowest concentration of 0.1 mg/mL. At and above 0.5 mg/mL 
concentration, both E1 and E2 extracts caused an unexpected increase in cell viability. Such 
false negative effect had been observed with crude extracts from some mushroom species 
(Smith et al., 2017; Deo et al., 2019) and is most likely due to chemical(s) in extracts interacting 
with MTT leading to colored solution. In comparison, extract 4 only showed little effect on cell 
































Figure 10 Dose-dependent assessment of cell viability by crude extracts isolated from F. 






2.2.2.3 Fomitopsis pinicola (#65) 
      The results of dose-dependent MTT assays performed using extracts from Fomitopsis 
pinicola (#65) are shown in Figure 11. Extracts 1 and 2 dramatically reduced cell viability to 
approximately 20% by 0.1 mg/mL. Extract 3 reduced cell viability to 60% at the highest dose 

































Figure 11 Dose-dependent assessment of cell viability by crude extracts isolated from F. 
pinicola. (#65) Error bars are standard deviation. 
2.2.2.4 Fomitopsis pinicola (#77) 
      Results of dose-dependent MTT assays of extracts 1-4 from Fomitopsis pinicola (#77) are 
shown in Figure 12. The results show that extracts 1 and 2 reduced cell viability to 20% at the 
lowest concentration of 0.1 mg/mL. Extract 3 exerted dose-dependent inhibitory effect leading 
to 20% cell viability at the highest concentration of 1 mg/mL. In contrast, extract 4 had no 


































Figure 12 Dose-dependent assessment of cell viability by crude extracts isolated from F. 
pinicola. (#77) Error bars are standard deviation. 
2.2.2.5 Phaeolus schweinitzii (#57) 
      Results of dose-dependent MTT assay of extracts 1-4 from P. schweinitzii (#57) are shown 
in Figure 13. Extracts 1 and 2 reduced cell viability to 20% and 40% at 0.25 mg/mL 
respectively. At higher concentrations, especially for E2, dark brown colored solution appeared 
upon addition of MTT. This could interfere with reading plate process and gave rise to the false 
negative results as shown in Figure 13. Extracts 3 and 4 also reduced cell viability to 20% but 



































Figure 13 Dose-dependent assessment of cell viability by crude extracts isolated from P. 
schweinitzii. (#57) Error bars are standard deviation. 
2.2.2.6 Phaeolus schweinitzii (#58) 
      The dose-dependent MTT assays on fractions from Phaeolus schweinitzii (#58) showed 
that extract 1 exhibited growth-inhibitory activity; it reduced cell viability to under 20% at 0.1 
mg/mL, and the effect increased with the increasing dose, which might be the color of the 
extraction interfering with the MTT reagent, resulting in false absorbance. Extracts 3 and 4 


































Figure 14 Dose-dependent assessment of cell viability by crude extracts isolated from P. 
schweinitzii. (#58) Error bars are standard deviation. 
2.2.2.7 Phaeolus schweinitzii (#60) 
      Results of dose-dependent assay of Phaeolus schweinitzii are shown in Figure 15. The 
results show potent effect by extract 3, reducing cell viability to 20% at 0.25 mg/mL. Extract 
4 reduced cell viability to 40% at 1 mg/mL. Extract 1 is the most potent, reducing cell viability 
to 20% at the lowest concentration of 0.1 mg/mL At and above 0.25 mg/mL, E1 exhibited false 
negative effect as mentioned above. Extract 2 only had modest effect, reducing cell viability to 


































Figure 15 Dose-dependent assessment of cell viability by crude extracts isolated from P. 
schweinitzii. (#60) Error bars are standard deviation. 
2.2.2.8 Phaeolus sp. (#71) 
      Results of dose-dependent assay of Phaeolus sp. are shown in Figure 16. The results 
demonstrate potent effect by extract 1, reducing cell viability to 10% at 0.1 mg/mL. Both 
Extracts 2 and 3 reduced cell viability to 30% at 1 mg/mL. Extract 4 only had modest effect, 
reducing cell viability to 60% at the highest concentration of 1 mg/mL. 




Figure 16 Dose-dependent assessment of cell viability by crude extracts isolated from 
Phaeolus sp. (#71) Error bars are standard deviation. 
        In this study, extracts E1, E2 and E3 from F. pinicola inhibited the growth of cancer cells 
dramatically, which were confirmed by previous studies (Wu et al., 2014 & Choi et al., 2007). 
Extract E4 of F. pinicola had no significant inhibitory effect on HeLa cells which is in 
agreement with the existing literature (Smith, 2017). Extracts E1 and E3 from P. schweinitzii 
showed strong growth-inhibitory on HeLa cells, while other two extracts did not exhibit potent 
inhibitory activity. 
       The primary screening method demonstrated results regarding the therapeutic potentials 
of extracts from the eight BC mushrooms studied here, summary of the results are shown in 
Table 12. The main challenge of this project is the purification and structural elucidation of the 
compounds from mushrooms. The reason for selecting Phaeolus sp. for further studies is that 
not many researches have been reported on the anti-cancer activity of this mushroom specie, 
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chapter 3 of this thesis will investigate in detail of the purification and structural elucidation of 
the small molecules from E1 extract of Phaeolus sp.; more information about this mushroom 
is shown in chapter 3. 
Table 12 Summary of twenty-eight crude extracts isolated from seven BC mushroom 









E1 (80% ethanol) 38.63 
E2 (50% methanol) 55.39 
E3 (water) 25.92 




E1 (80% ethanol) 54.07 
E2 (50% methanol) 49.25 
E3 (water) 20.72 




E1 (80% ethanol) 33.81 
E2 (50% methanol) 21.73 
E3 (water) 54.99 




E1 (80% ethanol) 32.68 
E2 (50% methanol) 37.21 
E3 (water) 19.25 




E1 (80% ethanol) 37.70 
E2 (50% methanol) 70.16 
E3 (water) 24.66 




E1 (80% ethanol) 56.15 
E2 (50% methanol) 64.02 
E3 (water) 32.77 




E1 (80% ethanol) 56.98 
E2 (50% methanol) 80.48 
E3 (water) 25.84 
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E4 (5% NaOH) 39.74 




























Chapter 3 Purification, identification and characterization of a growth-inhibitory 
compound from Phaeolus sp. 
     This chapter focuses on Phaeolus sp. (#71) which was collected from Pesuta Shipwreck 
Trail in Naikoon Provincial Park, Haida Gwaii, BC. The samples were morphologically and 
genetically identified as a member of the genus Phaeolus. Using the BLAST program, the 
sequence obtained from our collection matched 100% in the GenBank database to a voucher 
specimen identified as Phaeolus sp. by Jonathan Frank at Southern Oregon University, who 
believes it may be an undescribed species (Frank, personal communication); further research 
will need to be done to determine its identity. This mushroom was selected for purification and 
characterization to potentially discover novel compounds. Part A of this chapter focuses on the 
purification, characterization and structural elucidation of a growth-inhibitory compound from 
the E1 (80% ethanol) extract of Phaeolus sp.  Part B focuses on isolating other small molecules 
from Phaeolus sp. 
Part A: Purification and characterization of hispidin from Phaeolus sp. 
3.1 Purification and chemical characterization strategies 
      Numerous studies describing the therapeutic compounds medicinal fungi possess have 
been published (Pennerman et al., 2015). To understand these compounds better, one must 
undertake their purifications. Generally, the purification strategies for bioactive compounds is 
dependent on the nature of compounds. Liquid-liquid extraction is first employed to purify the 
compounds based on the polarity. After this, techniques like size-exclusion chromatography 
(e.g., Sephadex-LH-20), ion-exchange chromatography (e.g., DEAE Sephadex), and high-
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performance liquid chromatography (HPLC) are used for further purification. When the 
purification process is finished, analytical instruments like LC-MS (Liquid Chromatography-
Mass Spectrometry), GC-MS (Gas Chromatography-Mass Spectrometry), Fourier transform 
infrared spectroscopy (FTIR) and NMR (Nuclear Magnetic Resonance) are used to characterize 
the target compounds further. 
3.2 Materials and methods 
3.2.1 Large scale chemical extraction of Phaeolus sp. 
       The Phaeolus collection (#71) was finely powdered using a hammer mill, and large-scale 
extraction of extract E1 (80% ethanol) was performed manually using a hot plate. After that, 
the extracts were concentrated, pH neutralized and lyophilized using a Labconco freeze dryer 
and finally stored at -80°C. 
3.2.2 Liquid-liquid extraction (phase separation) 
       Liquid–liquid extraction or phase separation is a method to separate compounds based on 
relative solubility in two different immiscible liquids, usually water (polar) and an organic 





Figure 17 Illustration of the liquid-liquid extraction technique  
       At first, 100 mg of E1 extract (80% ethanol) powder was added in the extraction flask. 
Then, 40 mL of water was added to the flask as a primary solvent. Later, an equal volume (40 
mL) of ethyl acetate was added and the sample was dissolved in two layers. The flask was 
shaken to ensure that the separation of compounds between the two layers was maximized. 
After five minutes (or until the layers separated) the layers were observed (Figure 17). Each 
layer was collected into a different beaker. The upper layer (ethyl acetate layer) was dried by 
heating on a hot plate at 65 °C. The lower layer (water layer) was lyophilized using Labconco 
Freeze dryer. After obtaining the two dried samples, the yield was calculated and the two layers 






3.2.3 Sephadex™ LH-20 (size exclusion chromatography)  
      Size exclusion chromatography was also performed for better separation of the compounds 
in the crude ethyl acetate extract. During this purification process, the molecules were separated 
by their size as they passed through the stationary and mobile phase (100% Methanol) packed 
in the column. The larger molecules cannot fit in the pores of the stationary media and they 
flow more quickly through the stationary phase, which causes them to be eluted first. The 
smaller molecules easily penetrate the pores of the medium, causing them to flow slowly and 
elute out of the column later. Due to this physico-chemical property, Sephadex™ was selected 
to do the next step of purification.     
      Sephadex™ LH-20 is a liquid chromatography medium designed for natural product 
isolation (Datta et al., 2013). Since the medium is Sephadex LH-20, the method is also termed 
as Sephadex LH-20 column chromatography. Sephadex™ LH-20 is prepared by 
hydroxypropylation of cross-linked Sephadex G-25 dextran and an organic solvent is used as 
a mobile phase. This LH-20 resin has both hydrophilic and hydrophobic characteristics, which 
make it swell in aqueous solution and organic solvents. In my study, the mobile phase used was 
100% methanol as the mobile phase is based on the solubility of active compounds (ethyl 
acetate layer). Two types of columns, including a 22 mL column (micropipette) and 400 mL 
(C26/100 column), were used for packing the resin.  
3.2.3.1 Sephadex™ LH-20 resin swelling and column packing 
      The swelling ratio of Sephadex™ LH-20 resin to methanol was 1:4. Firstly, Sephadex™ 
LH-20 dry powder was transferred into a beaker and soaked in excess methanol to swell 
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overnight. After the resin was completely soaked with 100% methanol, the excess methanol 
was removed from the slurry. Methanol was degassed for 2-3 hours to ensure that the mobile 
phase had no dissolved gases. Otherwise, the gas would be pumped into column and crack the 
resin.  
      Two different types of columns were used for the purification. To pack a small sized column 
(22 mL), a 25 mL serological pipette (Sarstedt, Germany) was used as a column, and a cotton 
plug was used to hold the resin above the tip of the pipette and also ensure the mobile phase 
(methanol) could flow out of the column; the column was first packed with a total of 22 mL of 
resin under the influence of gravity. As for 400 mL (C26/100) (GE Healthcare) glass columns, 
the swollen resin was transferred to the columns first. The top and lower adapters were used to 
support the resin in the glass column, and the top of the column was linked to the solvent 
reservoir. The Pump P-50 (Pharmacia Biotech) was used to pump the methanol solvent to flow 
through the column for packing and washing at a flow rate of 2 mL/min. The column was 
required to equilibrate with degassed methanol for at least two column volumes between every 
run. 
3.2.3.2 Sample loading and fractions collection 
      The sample was prepared using the active extract from the upper layer (ethyl acetate layer) 
of the liquid-liquid extraction and methanol (100%) was used to reconstitute the sample. The 
final concentration of loading sample was 40 mg/mL. The sample was centrifuged before 
loading onto the column to remove the impurities which could be trapped in the resin. For a 22 
mL column, the sample was loaded onto the column using a micropipette (Thermo Fisher 
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Scientific, USA). The volume of the sample (ethyl acetate layer) loaded was 2% (440 μL) of 
the packed column volume. Fraction collection was based on gravity. The sample (8 mL) was 
introduced into the large (400 mL) (GE Healthcare) columns with the help of a syringe in a 
three-way switch (Figure 18). 
 
Figure 18 Photograph of the Sephadex™ LH-20 size exclusion technique using a large 
C26/100 column (GE Healthcare) and the mobile phase (degassed methanol) 
      The flow rate of the mobile phase for C26/100 columns was 2 mL/min. An automatic 
fraction collector (Pharmacia Biotech) was used to collect fractions, and the volume of the 
collected fractions was 14 mL. After collection, the fractions were stored in a cold room (4°C) 
before assessment for growth-inhibitory activity.         
3.2.3.3 Sephadex™ LH-20 column clean-up, unpacking and storage 
       After each run is finished, the columns were washed to ensure no sample remained in the 
resin. The original degassed mobile phase (100% methanol) was used to wash the resin at 1.5 
times the actual flow rate and with mobile phase volume twice the bed volume. However, if 
the sample was sticky and oily, the resin must be washed with NaOH (5%), at 1 mL/min flow 
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rate with half the column bed volume, then twofold of the column bed volume of water was 
used to wash the resin, at 1.5 mL/min flow rate to elute both the remnant loading sample and 
NaOH residue. Finally, two-column bed volume of degassed mobile phase were used to run 
through the column to ensure the long shelf life and reusability of the resin. After the column 
was washed, the resin was removed from the column and stored in an Erlenmeyer flask in 
degassed 100% methanol at 4°C to prevent any microbial contamination of the resin. 
3.2.4 UV absorbance analysis 
      A nanodrop spectrophotometer (Thermo Fisher Scientific, SA) was used to determine the 
maximum UV absorbance (λmax) of bioactive fractions 39 to 42 from the Sephadex LH-20 
(400 mL). After calibration with water, the spectrophotometer was blanked with HPLC grade 
methanol. The sample peddle was rinsed with autoclaved milli-Q water and wiped with 
Kimwipe paper before analyzing the sample. A 2 μL sample was used to determine the λmax 
of the fractions. The λmax for fractions was read at around 270 nm, which was later used in 
HPLC analysis of the active fractions. 
3.2.5 High performance liquid chromatography (HPLC-UV) analysis 
       HPLC is a powerful method for separation and purification of natural products (Adams & 
Nakanishi, 1979), which yields an excellent separation in a short time. Due to this, it was 
chosen to further purify the bioactive compounds collected from the Sephadex LH-20 fractions. 
HPLC operates under high pressure to push the mobile phase and the sample through the 
stationary phase. The Agilent 1260 Infinity Systems (HPLC) was used to purify the growth-
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inhibitory compound. The HPLC system was equipped with solvent systems, a sample 
injection valve, detector, controller, and computer to control the system and display results. 
      Reverse-phase HPLC is the most common type of HPLC used (Robards et al., 1994). In 
this study, RP-HPLC was used to isolate the growth-inhibitory compound. RP-HPLC has a 
nonpolar hydrophobic stationary phase and a moderately polar solvent as a mobile phase. 
Sample elution is based on polarity; the highly polar compounds elute first, and the non-polar 
compounds elute later (Sundaram et al., 2009). As a result, the non-polar (hydrophobic) 
molecules in the mobile phase tend to interact with the non-polar stationary phase more, while 
the polar molecules in the mobile phase pass through faster and elute from the column first. 
      Water is the most polar solvent so it can repel the hydrophobic molecules into the stationary 
phase more than other solvents, therefore, it causes longer retention times (Realini, 1981). 
When adding another organic solvent to the mobile phase system, the polarity could be 
modified, this causes the solvent system to no longer retard the sample in the stationary phase 
and thus spend less time in the column and elutes earlier. 
      The solvents used as the HPLC mobile phase were chosen based on their appropriateness 
to the RP-HPLC. Water and methanol were selected to consist the solvent system. Water was 
used because it is miscible, chemically non-reactive, has low viscosity, low UV absorbance, 
and high solubility, while the HPLC-grade methanol was selected based on good solubility of 
the sample.  
       A gradient elution method was used during all HPLC purifications to provide separations 
of mixture. The gradient elution method contains two or more mobile phases which differ in 
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polarity. The solvent system started with 30/70% water/methanol and ended at 40/60% water 
to methanol over nine minutes. The mobile phase was automatically degassed through the 
degasser system of the HPLC before entering the quaternary pump. The quaternary pump 
controls the flow rate as well as the gradient of the solvent system. The flow rate for the gradient 
mobile phase was set at 1.0 mL/min.  
      Samples (bioactive LH-20 fractions) were filtered using a 0.2 μm filter (Sarstedt, Germany) 
before injecting into the system. The wavelength (nm) used to visualize UV signal of bioactive 
compounds was 270 nm (based on reading from nanodrop spectrophotometer). The needle of 
the auto-sampler was programmed to wash every time before injection to prevent any cross 
contamination. The column was washed with the solvent system for at least 10 column 
volumes. The sample volume loaded onto the column was 10 μL (10 mg/mL). Each run took 9 
minutes to separate and elute all the peaks out of the column. The fraction collection was done 
based on the HPLC-UV. The fractions were collected into 8.0 mL glass vials using a fraction 
collector (Agilent infinity Lab 1260).                   
3.2.6 LC-MS analysis 
       LC-MS is a technique, which combines the separating power of HPLC, with the detection 
power of mass spectrometry (MS). Liquid chromatography separates mixtures into multiple 
components, and mass spectrometry provides structural identity of the individual components 
with high molecular specificity and detection sensitivity (McMaster, 2005). This technique can 
be used to analyze organic compounds efficiently (De Hoffmann, 2000). 
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       All LC-MS analyses were performed using Agilent 1260 Infinity Systems HPLC and 
Agilent 6120 quadrupole mass spectrophotometer. Mass spectrometry was performed using an 
active splitter, and a split ratio of 66:1. After separation of the sample components in the HPLC 
system, an Electrospray ionization (ESI) was used to convert separate sample species into ions 
in the gas phase, and the mass analyser was used to sort ions according to their mass to charge 
ratio (m/z). 
3.2.7 Nuclear magnetic resonance (NMR) analysis 
      Nuclear magnetic resonance spectroscopy, commonly referred to as NMR, has become the 
preeminent technique for determining the structure of organic compounds (Pretsch et al., 
2000). The structural elucidation of the compound was achieved using a Bruker 300 MHz NMR 
spectrophotometer. And 1D and 2D NMR spectra were recorded on a Bruker 300 spectrometer 
with a 5 mm Fourier easy probe.    
      One-dimension NMR is a technique used to probe the chemical environments of nuclei in 
molecules and recorded on a frequency axis while the intensity is represented as the 1D 
information of the molecules. This technique is highly automatable, reliable, and fast (Emwas 
et al., 2019). Although the 1D NMR spectrum of a natural product can be acquired rapidly, 
they are often complicated by peak overlap that can significantly impede the identification of 
a sample (Viant, 2003). Such an issue can be addressed by using two-dimensional (2D) NMR 
techniques by spreading out cross-peaks of resonances along the indirect dimensions that 
overlap in a 1D NMR spectrum, which can reduce the likelihood of peak overlap (Bingol et 
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al., 2014). The 2D NMR spectra can provide more information about a molecule than 1D NMR 
spectra, and are especially useful in determining the structure of a molecule. 
      One-dimension 1H NMR and 13C-NMR were performed to identify the proton and carbon 
atoms in our purified sample. The 2D-NMR spectroscopy correlation spectroscopy (COSY), 
heteronuclear single quantum coherence (HSQC) and heteronuclear multiple bond correlation 
(HMBC) were employed to further provide data about the sample. COSY is a 2D NMR method 
used to identify pairs of spin–spin coupled protons. In the spectrum, 1D NMR spectra of 
chemical shifts is indicated along a diagonal ridge running from the lower left to upper right 
corner of the plot. Cross peaks are produced by spin–spin coupling of two protons; most 
commonly, cross peaks are produced by adjacent protons. COSY is the most common form of 
2D NMR spectroscopy and is a routine and highly useful method for identifying molecules 
through their spin–spin couplings (Xi et al., 2006). HSQC spectra are 2D data matrices 
consisting of cross peaks of protons and carbons. It is a proton-detecting experiment, and it is 
more sensitive and less time-consuming to acquire. Also, it is richer in information as it 
simultaneously allows the list of directly bound 1H-13C pairs to be assembled (Szakács & Sánta. 
2015). The HMBC NMR experiment is probably the most useful and the most widely used 2D 
heteronuclear NMR method in the structural elucidation of organic molecular structures. 
(Furrer, 2012). It is a popular technique for multiple-bond heteronuclear chemical shift 
correlation (Martin & Zektzer, 1988). (1H-13C)-HMBC can provide correlations between 
protons and carbons that are two or three bonds apart from each other. The HMBC spectra is 
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important for the detection of quaternary carbons as it links separate structural fragments 
obtained from analysis of COSY and HSQC (Edison & Schroeder, 2010). 
      The magnets of the Bruker 300 MHz NMR spectrophotometer were shimmed properly 
before analysis of samples (Topspin 4.0.7). Approximately 7 mg of the sample was dissolved 
in deuterated acetone (CD3)2CO (99.96 % acetone-d and 0.3% Tetramethylsilane(TMS)) 
(Sigma Aldrich) and transferred directly into a 5 mm NMR tube (Kimble, USA). The final 
volume of the sample in NMR tube was approximately 1 mL. After performing the different 
types of NMR mentioned above, 1D and 2D NMR spectrums integrated together to provide 
clear information. 
3.2.8 Melting point 
       The melting point of a substance is the temperature at which the material changes from a 
solid to a liquid state, and it is one of the most widely used fundamental physical properties 
(Jain et al., 2004). Pure crystalline substances have a clearly defined melting point. 
Determining the melting point is a simple and fast method used to obtain a first impression of 
the purity of a substance, as even small quantities of impurities could change the melting point 
or expand its melting range.  
      The capillary method was used to determine the melting point of the purified compound 
using the MPA160 DigiMelt Student Melting Point System. A thin glass capillary tube 
containing little sample is placed into a heated stand in close proximity to a high accuracy 
thermometer. The temperature in the heating stand is increased, at a fixed rate, until the sample 
in the tube becomes liquid. Visual observations were taken to observe changes during the 
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melting point determination, including color change, loss of solvent and change in 
crystallization state. The onset point, when liquid clearly appears for the first time, is generally 
considered the start of the melting. The clear point corresponds to the stage of melting at which 
the substance becomes completely liquid. The melting point range is defined as the interval 
between the onset and clear points, which is an indicator of purity of a solid compound. 
3.3 Results 
3.3.1 Large scale chemical extraction of Phaeolus sp. 
       Large scale chemical extraction to isolate E1 was performed on the collection 71 of 
Phaeolus sp. The percent yield for E1 (80% ethanol) was 16.80% (Table 13). The extract can 
be partially dissolved in 100% methanol. 





Mass of E1 
extract (g) 
Yield (%) 
71 50.217 8.441 16.80 
                       
3.3.2 Liquid-liquid extraction (phase separation) 
        Liquid-liquid extraction performed on E1 of Phaeolus sp. resulted in two distinct layers. 
The lower layer was water and the top layer was ethyl acetate. The color of the aqueous layer 
was yellow, and it contained approximately 45% yield of product. The color of the upper 
organic layer was brown; The percent yield from the top ethyl acetate layer was 33.50% (Table 
14). Furthermore, solubility of both layers was determined in order to perform growth-
inhibitory assays; both extract samples were soluble in methanol.  
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Table 14 Percent yield of three layers based on liquid-liquid extraction (Phase separation) 



















Cream 8.90 44.50% Yes 
100% 
Methanol 
      The dose-dependent MTT assay was performed on lyophilized samples from the two layers 
of the liquid-liquid extraction; HeLa cell plating and treatment was described in section 2.1.5. 
The final concentration of the methanol was less than 1% in each well to prevent non-specific 
toxicity to cells. The doses tested on HeLa cells were 0.05 and 0.1 mg/mL. 
                
Figure 19 Assessing the water and ethyl acetate layers from E1 extract for anti-
proliferative activity. Two different concentrations of water and ethyl acetate layers were 
added to HeLa for 48 hours followed by assessment of cell viability using MTT assay. The 
graph shows results from one biological replicate (n=1). Error bars are standard deviation. 
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        As shown in Figure 19, strong growth-inhibitory activity was exhibited by the upper ethyl 
acetate layer. The cell viability was around 20% at both 0.1 and 0.05 mg/mL and results were 
consistent. At 0.1 mg/mL, the water layer also exhibited potent growth-inhibitory activity. 
However, in general, as compared to the ethyl acetate layer, the water layer had less potent 
activity against HeLa cells. Based on the MTT results, it was decided to proceed with 
purification of bioactive compounds from the upper ethyl acetate layer. 
3.3.3 Assessing post-Sephadex™ LH-20 fractions collected from a 22 mL column for 
bioactivity 
       Fractions from the 22 mL sized Sephadex LH-20 column were collected in 1.5 mL 
Eppendorf tubes and the final volume of each fraction was around 1.3 mL. Fractions 25-35 
were pale yellow in color, suggesting most compounds were present in these fractions. After 
collection, these tubes were put in racks and left in a fume hood for three days to evaporate the 
excess solvent. The dose-dependent MTT assay was performed to test the activity of these 
fractions, HeLa cells (1500 cells/well) were plated and after 24 hours of incubation, the cells 
were treated with 2 μL of the fraction and 98 μL of EMEM with 10% FBS. The final 
concentration of methanol in each well was maintained at 1% which was non-toxic to the cells. 
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Figure 20 Assessing anti-proliferative activity of fractions collected from 22 mL size 
Sephadex™ LH-20 column.  Effect of 2 μL from 22 mL size post-Sephadex™ LH-20 
fractions on HeLa cell viability. The graph shows results from one biological replicate (n=1). 
Error bars are standard deviation. 
        Fractions 25 to 32 inhibited the HeLa cell viability compared to the control (Figure 20). 
Weak growth-inhibitory activity was observed for other fractions except for fractions 25 to 32.  
Given that the inhibitory activity was observed in later eluting fractions, it is likely that the 
bioactive compounds are small in size. 
3.3.4 Assessing post-Sephadex™ LH-20 fractions collected from a 400 mL column for 
growth-inhibitory activity 
       After bioactivity was detected in specific fractions collected from the small Sephadex 
column (22 mL), the technique was scaled up to 400 mL using a C26/100 (GE Healthcare, 
Quebec) column. Fractions were collected in 15 mL tubes (Sarstedt) and the final volume of 
each fraction was around 5 mL. After collection, these tubes were left in the fume hood to 
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evaporate excess solvent. The MTT assay (1500 cells/well) was performed using fractions (14 
mL each) obtained by running a total 320 mg of the E1 (80% ethanol extract) ethyl acetate 
layer of Phaeolus sp. through a 400 mL Sephadex™ LH-20 column. The results of the MTT 
assay using the fractions are shown in Figure 21. 
    
Figure 21 Assessing anti-proliferative activity of fractions collected from a 400 mL 
Sephadex™ LH-20 column. Effect of 2 μL from 400 mL size post-Sephadex™ LH-20 
fractions on HeLa cell viability. The graph shows results from one biological replicate (n=1). 
Error bars are standard deviation. 
         Fractions 39 to 42 reduced the HeLa cell viability dramatically as compared to the 
control, suggesting the presence of bioactive compounds in these fractions. The results were 
consistent with the results from the 22 mL size column, the color of bioactive fractions were 
same, and the cell viabilities were similar, which inhibited at around 20%. The active fractions 
from the 400 mL column were further analyzed using analytical HPLC.  
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3.3.5 HPLC results  
3.3.5.1 Analytical 
      The purification process is depicted in Figure 22. 
                   
Figure 22 Flow chart diagram representing the method of compound purification from 
E1 (80% ethanol) extract of Phaeolus sp. 
       The resolution based on the analytical HPLC conditions was excellent: each peak was 
distinct and well separated (Figure 23). The retention time for the peak was 4.312 min (later 
confirmed to be hispidin). The percent abundance based on UV spectra for the peak was 
95.57%, and this peak was further aggregated and characterized.   
 
Figure 23 UV spectrum showing the relative abundance and retention time of peak at 
4.312 min at λmax 270 nm (using Agilent C-18 analytical column and Sephadex LH-20 active 
fraction sample).   
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3.3.5.2 HPLC-Mass spectroscopy (MS) analysis 
       The HPLC-purified compounds were protonated with the aid of 0.1% formic acid isocratic 
solution. Figure 24 shows the UV spectrum for confirmation of the purified compound. The 
percent abundance based on UV spectra for the peak was 99.33%. Spectra shown in Figures 
25 and 26 represent the MS SIM and scan signal of the peak respectively.. 
       The mass to charge ratio (m/z) of the protonated purified peak was 247.1 (Figure 27) which 
confirmed the presence of the target masses. The abundance of the targeted masses was also 
found to be higher in SIM mode than in the scan mode, confirming the presence of the 
compounds in the sample.  
 
Figure 24 UV spectrum confirming the purity of the compound [M+H]+ m/z 247.1 
detected at 4.312 min through ESI (Electrospray ionization) chamber.  
 
Figure 25 MS SIM spectrum showing the relative abundance and retention time of the 





Figure 26 MS scan spectrum showing the relative abundance and retention time of the 
compound with [M+H]+ m/z 247.1 detected at 4.312 min through ESI (Electrospray 
ionization) chamber. 
 
Figure 27 Integration of MS scan spectrum indicating the presence and abundance of 
compound with [M+H]+ m/z 247.1 visible at 4.567 min 
       In the MS scan spectrum, the ion peaks at m/z 247.1 [M+H]+ and m/z 269.1 [M+Na]+ in 
the positive mode, suggests the molecular weight of the purified compound to be 246.1 g/mol.  
3.3.6 Nuclear magnetic resonance (NMR) analyses 
       Comparing the NMR spectra found here (Tables 15-16) with previously published NMR 
data revealed that the growth-inhibitory compound in Phaeolus sp. is hispidin, which had been 




Table 15 1H NMR spectral data of purified compound (hispidin) obtained using Bruker 






H-3 5.36 J3,5=1.86 Hz 5.28 (d) 
H-5 6.11 J5,3=2.01 Hz 6.06 (d) 
H-7 6.65 J7,8=15.96 Hz 6.55 (d) 
H-8 7.24 J8,7=15.96 Hz 7.16 (d) 
H-10 7.15 J10,14=1.95 Hz 7.01 (s) 
H-13 6.84 J13,14=8.19 Hz 6.77 (d) 
H-14 7.01 J=6.21 Hz 6.88 (d) 
1Published NMR data of hispidin (Park et al., 2004) compared to this study.   
       The 1H NMR spectrum of hispidin (Figure 29) exhibited two doublets at 5.36 (d, 1H, H-3, 
J3,5=1.86 Hz) and 6.11 (d, 1H, H-5, J5,3=2.01 Hz), suggesting a long-range coupling of 4J in 
a lactone ring system. Two olefinic methine peaks attributable to a trans-1, 2-disubstituted 
double bond at the signals 6.65 (d, 2H, H-7, J7,8=15.96 Hz) and 7.24 (d, 2H, H-8, J8,7=15.96 
Hz). Three aromatic protons, which could be assigned to the protons of 1,3,4-tri-substituted 
benzene, can be observed at 7.15 (d, 1H, H-10, J10,14=1.95 Hz), 6.84 (d, 2H, H-13, 
J13,14=8.19 Hz), and 7.01 (dd, 2H, H-14, J=6.21 Hz).  
Table 16 13C NMR spectral data of purified compound (hispidin) obtained using Bruker 
Fourier A-300 NMR. 
Carbon Hispidin Hispidin1 
C-2 162.9 171.0 (s) 
C-3 89.8 89.4 (d) 
C-4 169.9 163.6 (s) 
C-5 100.1 101.5 (d) 
C-6 160.3 159.9 (s) 
C-7 116.6 116.1 (d) 
C-8 134.9 134.7 (d) 
C-9 127.8 127.2 (s) 
C-10 113.8 114.4 (d) 
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C-11 147.0 147.6 (s) 
C-12 145.5 145.9 (s) 
C-13 115.5 115.9 (d) 
C-14 120.7 120.3 (d) 
1Published NMR data of hispidin (Park et al., 2004) compared to this study.   
    The signals observed for the 13C NMR spectrum (Figure 30) of hispidin indicate the presence 
of 13 carbons in this structure. The signals for non-proton bearing carbons of hispidin (C-4, C-
2, C-6, C-11, C-12 and C-9) were observed downfield at 169.9, 162.9, 160.3, 147.0, 145.5 and 
127.8 ppm respectively. The signals for aromatic carbons (C-10, C-13 and C-14) were observed 
at 113.8 ppm, 115.5 ppm and 120.7 ppm. Two olefinic methine carbons C-7 and C-8 were 
observed at 116.6 ppm and 134.9 ppm respectively. The signals at 89.8 ppm and 100.1 ppm are 
due to two methine carbons C-3 and C-5 on the lactone ring. 
 
Figure 28 Chemical structure of hispidin 
      1H-1H COSY is a 2D method used for determining the signals arising from neighboring 
protons. The COSY spectrum as shown in Figure 31, the peaks show the coupled signals of 
neighboring protons. Cross peaks at 6.84 and 7.01 ppm are due to two neighboring aromatic 
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protons (H-13 and H-14). Two olefinic methine protons at position (H-7) display a cross peak 
at 6.65 ppm and 7.24 ppm with the proton at position H-8, suggesting they are neighbors. 
     Heteronuclear single quantum correlation (HSQC) is a two-dimensional spectrum which 
has two axes, one for protons (1H NMR) and the other for carbons (13C spectrum). HSQC 
provides detailed information about correlations between a carbon and its attached protons. 
The HSQC spectrum (Figure 32) of hispidin showed resonances for three aromatic protons 
7.15 ppm (H-10), 6.84 ppm (H-13) and 7.01 ppm (H-14), two olefinic methine protons 6.65 
ppm (H-7) and 7.24 ppm (H-8), and two methine protons 5.36 ppm (H-3) and 6.11 ppm (H-5) 
on the lactone rings. The carbons at position C-2, C-4, C-6, C-9, C-11 and C-12, displayed no 
resonance signals with the 1H spectrum, indicating the carbons are quaternary. 
     The 13C - 1H NMR heteronuclear multiple bond correlation (HMBC) 2D spectrum (Figure 
33) of hispidin showed long-range correlations from one singlet methine proton δ 5.36 to C-3, 
another proton δ 6.11 to C-3, C-6 and C-7, from two olefinic methine protons at δ 6.65 and 
7.24 to C-5, C-6, C-9, and C-10, from methine protons at δ 7.15 to C-9 and C-11, from methine 
protons at δ 6.84 to C-8, C-12, and C-14, and from methine protons at δ 7.01 to C-8, C-10, and 
C-12. 
     Based on the above described NMR data obtained from my experiments, the structure of 
the purified compound was determined to be hispidin (Figure 28), which has been previously 
isolated from the fungi P. linteus (Jang et al., 2010) and Inonotus hispidus (Bull.) P. Karst. 




Figure 29 1H -NMR spectrum of hispidin in (CD3)2CO containing 0.3% TMS 
 
 




Figure 31 1H - 1H NMR correlation spectroscopy (COSY) 2D spectrum of hispidin in 
(CD3)2CO containing 0.3% TMS. 
 
Figure 32 13C - 1H NMR heteronuclear single quantum coherence (HSQC) 2D spectrum 




Figure 33 13C - 1H NMR heteronuclear multiple bond correlation (HMBC) 2D spectrum 

















3.3.7 Physical properties of hispidin from Phaeolus sp. 
      The compound hispidin, purified using HPLC, was dried: it is yellow and has produced a 
fluffy needle-like powder (Figure 34). 
 
Figure 34 Hispidin from Phaeolus sp. 
3.3.8 Melting point 
      About 1 mg of hispidin was loaded into a capillary and placed into the chassis hole. A quick 
trial run was completed with a starting temperature of 70 °C and ramp rate of 2 ºC per minute. 
The trial run provided an estimation of the sample’s melting point. After this, a slow run was 
done to provide an accurate or true melting point range for the sample. The starting temperature 
was set at 210 °C, and the ramp rate was 0.5 ºC/minute. At 232.0 °C, a little liquid appeared 
on the sample, and at 233.0 °C, the powder sample turned into liquid. Meantime, another 
capillary with the same sample was also loaded into an oven and melted at the same time to 
improve the repeatability and accuracy of the melting point range determination. Table 17 
shows the melting point range. In this study, the purity of hispidin was greater than 99%, and 
operation process was completed twice which can be considered reliable.  
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Table 17 Melting point range of hispidin. 
Ramp Rate 
[°C/min] 
Onset Point - Clear Point [°C] Temp. Range [°C] 
0.5 232.0-233.0 1.0 
     The reported melting point of hispidin was different from the previously published melting 
points: the CAS DataBase List showed the melting point range of hispidin to be from 312 to 
315℃, while the Sigma-Aldrich Corporation database states the melting point as 237.5 to 238.5 
°C. Gonindard et al. (1997) indicated the melting point is 259 °C. Such differences could result 
from differences in the purity of hispidin or distinct melting point measuring systems and 
experimental operations. 
3.3.9 Percent yield of each step of the purification of Phaeolus sp. 
     Table 18 shows the percent yield at each step of the purification, the yield was calculated 
based on previous step of purification technique. 
Table 18 Techniques followed and percent yield of compounds from E1 (80% ethanol) 
extract of Phaeolus sp. 
Technique Yield (in mass) 
Yield based on 
technique (%) 
Powdered mushroom 
sample # 71 
50.217 g - 
E1 (80% Ethanol) 
Fraction weight 
8.476 g 16.88 
Liquid-liquid extraction 
yield. 
3.012 g 35.53 
Loaded on Sephadex™ 
LH-20 (400 mL) 
= 320 mg/run - 
Active fractions 
obtained from 
Sephadex™ LH-20 (400 
mL) 
~40.80 mg/run 12.75 
Sample purified by 
HPLC-UV 
10 mg/run - 
Hispidin 1.5 mg 15.00 
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Part B: In search of other small molecules from Phaeolus sp. 
3.4 Purification and chemical characterization strategies 
     Hispidin is a known compound, and its therapeutic properties and underlying mechanisms 
have been investigated as described in section 4.2.1. Some other purification techniques were 
used in this part to discover potential novel compounds other than hispidin in the mushroom 
Phaeolus sp. 
3.5 Materials and methods 
3.5.1 Silica gel chromatography 
Normal-phase liquid chromatography is an important complement to more frequently 
used reversed-phase liquid chromatography. It can be performed in organic mobile phases 
(adsorption liquid chromatography), where it can offer advantages for separation of low 
molecular weight, moderately polar molecules, and allow variability in selectivity by using 
different mobile phases (Soukup et al., 2013).  
Silica gel is a typical stationary phase used in normal phase liquid chromatography; it 
consists of a three-dimensional network of thousands of alternating silicon and oxygen bonds, 
with surface hydroxyl groups whose number and geometric arrangement determine the 
retention of the adsorbent. The slightly acidic silanol groups (Si-OH) in silica gel exist at the 
surface and extend into the internal channels of the pore structure. These hydroxyl groups 
interact with polar moieties by hydrogen bonding.  
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 An organic solvent or a mixture of solvents will flow down through the column of silica 
gel. Components of the sample separate from each other by partitioning between the silica gel 
and the mobile phase. Molecules with different polarities will partition to different extents, and 
then flow through the column at different rates. 
3.5.1.1 Solvent selection 
Solvent selection for achieving a good separation was important in this technique. A thin 
layer chromatography (TLC) plate sheet was used in this process to determine the suitable 
solvent system. TLC is a method for analyzing mixtures; it is a sensitive technique and takes 
little time for analysis (Touchstone, 1992). Some solvents were tested by TLC, as no more 
fractions except hispidin were observed on the TLC plates in a single solvent system (Figure 
39).   A single gradient solvent system with a slow change of solvent polarities was used as the 
mobile phase to flush the column, which provides a distinct adsorption strength (Snyder, 1978).  
During the gradient-elution process, mixtures of analytes whose polarities span over a large 
polarity range can be separated (Soukup et al., 2013).  
Elution of compounds in the column started with the first solvent as a mobile phase that 
has the lowest polarity, followed with other solvents as given in Table 19 (Snyder, 1978). Such 
a gradient solvent system was deemed to elute substances with different polarities out of the 
column gradually. Karami et al. (2010) have used a similar solvent system to successfully 










80% Toluene+20% Ethyl acetate 0.28 
40% Toluene+60% Ethyl acetate 0.34 
Ethyl acetate 0.38 
80% Ethyl acetate+20% Ethanol 0.48 
Methanol 0.73 
3.5.1.2 Silica gel column packing 
     The normal phase column was 30 cm × 1.5 cm, manually packed with silica gel. Silica gel 
(F60) particle size is between 40 to 63 μm, which is suitable for compounds with a molecular 
weight less than 1000. The FMI Lab pump (Fluid Metering, Inc) was used to pump out the 
solvents to flow through the column for packing. The column was first moistened and balanced 
by a solvent mixture of toluene and ethyl acetate (4:1). 
3.5.1.3 Sample loading and fraction collection 
     The sample was prepared using the E1 extract (80% ethanol) powder and methanol (100%) 
was used to reconstitute the sample. The final concentration of loading sample was 30 mg/mL. 
The sample was centrifuged before loading onto the column to remove the impurities. The 




Figure 35 Photograph of the silica gel chromatography using a 30 cm × 1.5 cm size column 
and the mobile phase. 
The flow rate of the mobile phase was 6 mL/min. The volume of the collected fractions 
was 6 mL. Five solvents with increasing solvent strength were used in this process as shown 
in Table 15. About 60 mL of each solvent was run through the column, which is almost double 
the column volume. After collection, the fractions were left in a fume hood and dried for further 
analysis. 
3.5.2 Small scale chemical extraction using hexane 
As 80% ethanol (E1) is a moderately polar solvent, then a non-polar solvent hexane was 
used to perform extraction of Phaeolus sp. in order to isolate other small molecules. A 
compound with an m/z of 283.2 was detected in the hexane extract. 
This extraction was performed manually, as hexane is highly flammable, and it corrodes 
plastics, rubber, and coatings. Therefore, a hot plate and magnetic stir bar cannot be used in the 
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extraction process. Firstly, 500 mg of Phaeolus sp. mushroom powder was added to 40 mL of 
hexane and stirred gently with a glass rod. The beaker was then covered with foil and left in 
the fume hood overnight. The following day, the hexane layer was collected into another beaker 
using a Pasteur pipette and dried in a fume hood. After obtaining the dried sample, the yield 
was calculated and further analyzed using LC-MS. 
3.5.3 HPLC-MS analysis 
3.5.3.1 Silica gel column fraction  
The HPLC-MS analysis of the silica gel fraction was performed using a Phenomenex 
Aqua® 5 μm C18 125 Å analytical column and isocratic solvent system of 70 % acetonitrile 
and 30 % water. The flow rate for the mobile phase was set at 1 mL/min. The sample (silica 
gel fraction 42) was filtered using a 0.2 μm filter (Sarstedt, Germany) before injecting 5 μL -
MS system.  
Mass spectroscopy was performed using an active splitter. The active splitter ratio used 
was 66:1. Scan mode was performed to determine the mass of ionized compounds in the peaks. 
A formic acid (0.1%) isocratic solution was used to ionize the sample compounds.  
3.5.3.2 Hexane extraction  
 HPLC-MS analysis of the hexane extract was performed using a Phenomenex Aqua® 5 
μm C18 125 Å analytical column and isocratic solvent system (two solvent system). The 
Sephadex LH-20 size based and silica gel polarity-based chromatography separations were not 
performed on this extraction. The composition of the isocratic mobile phase was based on 10 
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% water and 90% acetonitrile. The flow rate was set at 1 mL/min. The sample was filtered and 
10 μL injected into the HPLC-MS system. Mass spectroscopy was performed using an active 
splitter, and the split ratio used was 66:1. Scan and SIM modes were performed to determine 
the mass of ionized compounds in the peaks. A formic acid (0.1%) isocratic solution was used 
to ionize the molecules in the sample.  
3.6 Results 
3.6.1 Silica gel column fraction 
      To determine the appropriate solvent system for the E1 extract of Phaeolus sp., a series of 
solvents with different polarities were used during TLC spot test. The control for the TLC plates 
was hispidin. Figure 36 shows TLC plate spots test eluting with different solvents. No 
separation was observed, suggesting that a single solvent system may not be suitable for the 
separation.    
 
Figure 36 TLC of E1 of #71 Phaeolus sp. (lane 1), and hispidin (lane 2). The plates were 
eluted using toluene (A), chloroform (B), acetone (C), acetonitrile (D), ethanol (E) and 
methanol (F). Plates were visualized with UV light. 
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      The solvent system as shown in Table 15 was used to run through the column and in total 
53 fractions were collected from the silica gel column (Table 20). All the fractions were 
collected in glass tubes and the final volume of each fraction was around 6 mL. Fractions 42-
44 were yellow in color, suggesting that most compounds were present in these fractions. After 
collection, these fractions were left in a fume hood to evaporate the excess solvent, and finally 
analyzed using LC-MS. 




80% Toluene+20% Ethyl acetate 1-10 
40% Toluene+60% Ethyl acetate 11-20 
Ethyl acetate 21-30 
80% Ethyl acetate+20% Ethanol 31-40 
Methanol 41-53 
3.6.2 Hexane extraction 
     A small scale chemical extraction with hexane was performed on mushroom sample #71 
Phaeolus sp. The percent yield for the hexane extract was 0.42% (Table 21). The extract was 
dissolved in 100% methanol and further analyzed by LC-MS. 




Mass of hexane 
extract E1 (mg) 
Yield 
(%)  






3.6.3 HPLC-MS analysis 
3.6.3.1 Silica gel column fraction 
     The most abundant peak on the UV spectrum was observed at 3.301 min containing 90.62% 
of the sample (Figure 37). Figure 38 represents the MS scan spectrum, consistent with the UV 
spectrum. The mass to charge ratio (m/z) of the protonated peak at 3.301 min was 247.0 (Figure 
39), which is most likely to be hispidin, suggesting that hispidin is the dominant compound in 
E1 extract of Phaeolus sp., and the quantities of other potential constituents produced in this 
extract were possibly too small to be observed and detected. 
 
Figure 37 UV spectrum showing the relative abundance and retention time of at 3.031 
min at λmax 270 nm (using Agilent C-18 analytical column and silica gel fraction sample).   
 
Figure 38 MS scan spectrum representing the relative abundance and retention time of 





Figure 39 Integration of MS scan spectrum indicating the presence and abundance of 
compound with [M+H]+ m/z 247.0 visible at 3.242 min. 
3.6.3.2 Hexane extraction 
      The most abundant peak on the UV spectrum was observed at 3.114 min, containing 
35.44% of the sample mixture (Figure 40). The percent abundance of the UV peak visible at 
8.856 min was 26.82%, making it the second most abundant peak on the spectrum. The third 
abundant peak at 7.092 min was 21.79%. Figure 41 represents the MS scan signal; a major 
peak with m/z values of 283.2 can be observed at 9.214 min, which is consistent with the UV 
spectrum peak at 8.856 min.   
      The SIM mode and the m/z value of 283.2 were utilized to confirm the presence of this 
molecule. The m/z value of 247.0 was also set to identify the presence of hispidin in the sample. 
Figure 42 represents the SIM signal of the peaks. The abundance of the targeted mass 283.2 
was found to be much higher in the SIM mode than in the scan mode (Figure 45), confirming 
the presence of a compound in the sample. Figure 44 shows the m/z value of 247.0 at 3.295 
min, indicating this peak may be hispidin. The MS signals are visible with a slight time delay 
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because of the travel time through the 24-inch line from the UV spectrophotometer to mass 
spectrophotometer. 
 
Figure 40 UV spectrum showing the relative abundance and retention time of peaks at 
λmax 250 nm (using Agilent C-18 analytical column and Sephadex LH-20 active fraction 
sample).   
 
Figure 41 MS scan spectrum representing the relative abundance and retention time of 




Figure 42 MS SIM spectrum representing the relative abundance and retention time of 
the targeted masses, detected through ESI (Electrospray ionization) chamber. 
 
 
Figure 43 Integration of MS scan spectrum indicating the presence and abundance of 




Figure 44 Integration of MS SIM spectrum indicating the presence and abundance of 
compound with [M+H]+ m/z 247.0 visible at 3.295 min 
 
 
Figure 45 Integration of MS SIM spectrum indicating the presence and abundance of 
compound with [M+H]+ m/z 283.2 visible at 9.237 min 
3.6.3.3 Possibility of isolating novel compounds from Phaeolus sp. 
     HPLC-MS analyses of the hexane extraction have provided an insight into the possibility 
of isolating compounds other than hispidin from Phaeolus sp. The m/z value of the compound 
present in the hexane extract was 283.2, which could possibly be lactapiperanol A or 
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lactapiperanol C (purified from Lactarius piperatus (L.) Pers. (Yaoita et al., 1999). Figure 46 
shows the structures of compounds lactapiperanol A and lactapiperanol C. 
 
Figure 46 The structures of lactapiperanol A and lactapiperanol C. 
    However, the LC-MS spectra were not provided by Yaoita et al. (1999), so a comparison 
cannot be made. Figure 47 shows one predicted MS scan spectrum of lactapiperanol C from 
FooDB database which is similar to the spectra obtained from Phaeolus sp. (Figure 48). 








Chapter 4: General Discussion  
4.1 Screening BC wild mushrooms for growth-inhibitory activities 
      Most wild mushrooms in British Columbia remain unexplored, and their medicinal 
properties remain unknown. Therefore, one of the major objectives of this thesis was to screen 
several mushrooms collected from British Columbia forests, for their growth-inhibitory 
potential. This primary screening method using MTT assay provides a relatively fast procedure 
to find potential anticancer agents in mushroom extracts and justify progression into the next 
stage of exploration.  
      In this thesis, eight mushroom collections belonging to three species: Fomitopsis pinicola, 
Phaeolus schweinitzii and Phaeolus sp, were collected from Haida Gwaii in British Columbia 
and chosen for the investigation of their growth-inhibitory potential. 
4.1.1 Fomitopsis pinicola 
         In this study, extracts E1 and E2 from all F. pinicola specimens showed strong anti-cell 
viability activity, which is consistent with previous studies. Wu et al. (2014) revealed that the 
F. pinicola ethanol extract possesses anticancer activity both in vitro and in vivo, whereas the 
inhibitory effect of the water extract was less pronounced. Choi et al. (2007) demonstrated that 
the F. pinicola methanol extract had strong antitumor activity. Interestingly, 5% NaOH extract 
of F. pinicola had no significant inhibitory effect on HeLa cells (Smith, 2017), which is 
consistent with the results obtained in our study. 
       In recent years, many studies have reported on the biological function and chemical 
analysis of F. pinicola extracts. Wang et al. (2014) indicated that F. pinicola chloroform extract 
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could exert anticancer activity by inhibiting human colorectal cancer SW-480 cells viability 
with the IC50 of 190.28 µg/mL. Elsewhere, a chloroform extract of F. pinicola also 
demonstrated potent cell-growth inhibition activity, not only on in vitro murine sarcoma cancer 
S180 cells but also in mouse models by prolonging their lifespan (Gao et al., 2017). Wu et al. 
(2014) also documented F. pinicola ethanol extract significantly decreased tumor size with 
growth inhibitory ratio at 54% and increased the lifespan in mice bearing sarcoma-180 tumors.  
Furthermore, ethyl acetate and petrol ether extracts of F. pinicola were found to exhibit 
cytotoxicity against HeLa cell lines and hepatocellular cancer SMMC-7721 cell lines (Ren et 
al., 2006). One compound (3-acetoxylanosta-8,24-dien-21-oic acid), isolated from chloroform 
extract of F. pinicola, showed promising effect on human liver cancer SMMC-7721 cells and 
human breast cancer MCF-7 cells with inhibition rate at 77.63% and 90.29%, respectively (Sun 
et al., 2012). Shi et al. (2017) reported four lanostane triterpenes isolated from F. pinicola 
could inhibit breast cancer MCF-7 cell lines significantly. Table 22 provides a literature list of 













































































































(Shi et al., 
2017) 
       Because extensive research had been conducted on F. pinicola, this mushroom was not 
investigated further in this thesis. 
4.1.2 Phaeolus schweinitzii 
        In our study, extracts E1 and E3 of P. schweinitzii were found to possess the most potent 
growth-inhibitory effects. Hispidin and five new hispidin derivatives with antioxidant activity 
were isolated from P. schweinitzii (Han et al., 2013). P. schweinitzii is used for arsenic and 
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antimony volatilization in relation to sudden infant death syndrome (Pearce et al., 1998). Based 
on these results, it can be suggested that these extracts of P. schweinitzii are good candidates 
for future potential discovery of novel anti-cancer compounds. 
4.2 Purification, identification and characterization of a growth-inhibitory compound 
from Phaeolus sp. 
       Phaeolus sp. was the mushroom selected for this study because limited studies have been 
performed on this mushroom regarding its anti-cancer activity, and preliminary work (as 
described in section 2.2.2.8) suggested that the ethanol extract of the mushroom was able to 
inhibit cancer cells in vitro. Phaeolus sp. (#71) sample was also more readily available and of 
substantial quantity compared to other P. schweinitzii collections.  
4.2.1 Purification and characterization of compound hispidin from Phaeolus sp. 
       In this part of my MSc thesis, I have successfully developed a purification method to 
isolate one growth-inhibitory compound, hispidin, from Phaeolus sp.  
       The first purification step is liquid-liquid extraction with ethyl acetate and water. The 
cytotoxic MTT assay was performed to assess the inhibitory activity. Growth-inhibitory 
compounds were found in the ethyl acetate layer, suggesting that they are more hydrophobic. 
Further purification was achieved using Sephadex LH-20 size exclusion chromatography 
which could provide information about the size of the bioactive molecules, as smaller 
molecules will elute at later fractions when using a Sephadex LH-20 column. The last 
purification step was HPLC to isolate the major growth-inhibitory small molecule present in 
the bioactive fractions from Sephadex LH-20. After collection of the bioactive small molecule 
from HPLC, followed by 1D and 2D NMR analyses, the obtained spectra were compared with 
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previously published NMR data (Park et al., 2004, Lee et al., 2008) and finally, the compound’s 
identity was confirmed to be hispidin. The final percent yield of hispidin was 0.115%.  
         Hispidin was first discovered from Inonotus hispidus (Bu'Lock et al., 1962). It is a phenolic 
compound, which has various biological functions. It can be synthesized (Gonindrd et al., 
1997) and purified from different mushrooms, using a variety of purification strategies. 
Benarous et al. (2015) used silica gel column chromatography and gradient eluent to purify 
hispidin from the mushroom I. hispidus, however, the extraction process and data were not 
reported in detail. The compound was also extracted from the mushroom P. linteus using only 
silica gel column chromatography, and the purity was greater than 90%, as assessed by HPLC-
UV (Jang et al., 2010). In our study, after size-exclusion chromatography, the purity was greater 
than 95% as assessed by HPLC-UV, and the purity was greater 99% after HPLC purification.  
     The previous studies which isolated hispidin from mushrooms only used the silica gel 
polarity-based chromatography to do the separation, which is not efficient, as some other 
components with similar polarities can also be eluted with hispidin simultaneously, resulting 
in an impure product. Thus, Sephadex LH-20 size-based chromatography can be employed as 
an intermediate step, as it is an effective method to purify small molecules (Nandi, 1976). 
Finally, HPLC can be utilized for the separation of molecules by their polarities, as a crucial 
step to obtain a higher purity of the final product. By comparison with those purifying methods 
of hispidin from other mushrooms, this purification strategy of phase separation, size-exclusion 
chromatography and HPLC can be considered an efficient way to isolate small molecules. 
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       Hispidin was found to be bioactive and effective in many manners. It exerts antitumor 
effects against human pancreatic BxPC-3 cancer cells and cancer stem cells while also being 
capable in sensitizing pancreatic cancer stem cells from chemotherapy medication 
(gemcitabine) (Chandimali et al., 2018). Hispidin also induces intrinsic and extrinsic apoptotic 
pathways mediated by reactive oxidative species (ROS) in both BxPC-3 cancer cells and cancer 
stem cells (Chandimali et al., 2018). In addition, hispidin is known to be more cytotoxic 
towards certain cancer cell lines and cancer cells (human cancerous keratinocytes SCL-1 cell 
line, human cancerous pancreatic duct Capan-1 cell line, adenocarcinomic human alveolar 
basal epithelial cells A549, hepatocellular carcinoma cells (Bel7402), and human pancreatic 
ductal adenocarcinoma cells (Capan-1)) than normal human MRC-5 cells because it inhibits 
protein kinase enzymes (Gonindard et al., 1997). The compound was found to induce 
autophagic and necrotic death of SGC-7901 gastric cancer cells via lysosomal membrane 
permeabilization through inhibiting tubulin polymerization (Lv et al., 2017). Furthermore, Lim 
et al. (2014) found that hispidin could significantly decrease cell viability in both mouse colon 
cancer CMT-93 cells and human colon cancer HCT 116 cells. 
      Based on the above description, it is clear that hispidin had been widely studied for its 
medicinal properties and underlying mechanisms. Therefore, the biological activities were not 
further pursued in this project. 
4.2.2 In search of other small molecules from Phaeolus sp. 
       As hispidin is a well-studied compound, other purification methods were used to explore 
other potential small molecules from Phaeolus sp. Silica gel chromatography was first 
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performed to separate potential compounds in the E1 extract of Phaeolus sp. The collected 
silica gel fraction was analyzed by HPLC-MS, and it was concluded that hispidin was the major 
compound present in the E1 extract of Phaeolus sp. A 80% ethanol is a moderately polar 
solvent, and is likely to extract hispidin.  
      The non-polar solvent hexane was therefore used to perform an extraction of Phaeolus sp., 
aiming to isolate other small molecules. The hexane extract was subjected to HPLC-MS 
analysis, and the m/z of the most abundant compound present was 283.2, which could be 
compounds lactapiperanol A or lactapiperanol C (purified from L. piperatus) (Yaoita et 
al.,1999), or a novel compound. Both lactapiperanol A and C were not found to possess 
medicinal activity. However, due to the low yield of hexane extract and insufficient Phaeolus 
sp. mushroom powder, not enough sample could be collected for further investigation. Supplies 
of material and low yield of natural compound are often a challenge for studies of natural 
products (Beutler, 2009). 
4.3 Conclusion 
        Previous studies have indicated that British Columbian wild mushroom species possess 
immuno-modulatory and growth-inhibitory activities. This is the second study in Dr. Lee’s lab 
describing purification and characterization of small molecules from Canadian wild 
mushrooms. This MSc thesis sheds further light on the anti-cancer and therapeutic potential of 
BC mushrooms and the purification of their small molecules. The results obtained from this 
study are providing basic knowledge for future investigations into discovering potential novel 
compounds from BC wild mushrooms. For example, the crude water extracts from mushroom 
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Phaeolus sp. that contain growth-inhibitory activity, were not studied here, and might serve as 
a potential avenue for new compound discovery. This study has successfully led to the 
purification of hispidin from Phaeolus sp. using phase separation, size-exclusion 
chromatography and HPLC. A compound with an m/z of 283.2 was identified in the hexane 
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